IL6 and COVID-19: In a study conducted during the pandemic, a high prevalence of candidemia was observed, concisely in patients treated with tocilizumab due to COVID-19.Based on the results of the aforementioned study, it can be speculated that the suppression of the IL-6 response might contributeto this blood infection [ 29].